Jim Simons
KZR

Jim Simons’s Kezar Life Sciences KZR Stock Holding History

Jim Simons’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Buy
188,426
+57,141
+44% +$372K ﹤0.01% 2093
2025
Q4 		$826K Buy
131,285
+15,400
+13% +$89.8K ﹤0.01% 2372
2025
Q3 		$452K Buy
115,885
+28,601
+33% +$117K ﹤0.01% 2842
2025
Q2 		$400K Buy
87,284
+1,700
+2% +$7.29K ﹤0.01% 2945
2025
Q1 		$418K Sell
85,584
-2,101
-2% -$12.8K ﹤0.01% 2812
2024
Q4 		$589K Sell
87,685
-42,022
-32% -$313K ﹤0.01% 2769
2024
Q3 		$1M Buy
129,707
+51,860
+67% +$313K ﹤0.01% 2445
2024
Q2 		$467K Sell
77,847
-55,960
-42% -$425K ﹤0.01% 2720
2024
Q1 		$1.21M Buy
133,807
+4,615
+4% +$42K ﹤0.01% 2371
2023
Q4 		$1.22M Buy
129,192
+68,322
+112% +$601K ﹤0.01% 2271
2023
Q3 		$724K Sell
60,870
-4,728
-7% -$83.8K ﹤0.01% 2514
2023
Q2 		$1.61M Sell
65,598
-3,970
-6% -$103K ﹤0.01% 2143
2023
Q1 		$2.18M Buy
69,568
+61,258
+737% +$3.54M ﹤0.01% 1980
2022
Q4 		$585K Buy
8,310
+3,345
+67% +$248K ﹤0.01% 2863
2022
Q3 		$427K Sell
4,965
-6,495
-57% -$631K ﹤0.01% 3021
2022
Q2 		$948K Sell
11,460
-15,760
-58% -$1.39M ﹤0.01% 2760
2022
Q1 		$4.52M Sell
27,220
-5,800
-18% -$832K 0.01% 1670
2021
Q4 		$5.52M Sell
33,020
-202
-0.6% -$22.8K 0.01% 1469
2021
Q3 		$2.87M Buy
33,222
+640
+2% +$42.4K ﹤0.01% 1818
2021
Q2 		$1.77M Sell
32,582
-30
-0.1% -$1.7K ﹤0.01% 2338
2021
Q1 		$1.94M Sell
32,612
-2,380
-7% -$139K ﹤0.01% 2249
2020
Q4 		$1.83M Buy
34,992
+2,120
+6% +$118K ﹤0.01% 2176
2020
Q3 		$1.59M Sell
32,872
-10,790
-25% -$516K ﹤0.01% 2264
2020
Q2 		$2.26M Buy
43,662
+36,520
+511% +$1.84M ﹤0.01% 2122
2020
Q1 		$311K Sell
7,142
-30
-0.4% -$1.22K ﹤0.01% 2963
2019
Q4 		$288K Sell
7,172
-898
-11% -$27.6K ﹤0.01% 3083
2019
Q3 		$265K Buy
+8,070
New +$390K ﹤0.01% 3069

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Jim Simons's KZR Position: Q1 2026 in Review

Jim Simons increased its Kezar Life Sciences (KZR) stake by 44% in Q1 2026, buying an estimated $372K and bringing the position to 188,426 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Jim Simons first reported a position in KZR in Q3 2019 and has held it in 27 quarters since. The position peaked at $5.52M in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Jim Simons held 188,426 shares of Kezar Life Sciences worth $1.4M as of Q1 2026.
  • Jim Simons bought 57,141 Kezar Life Sciences shares in Q1 2026, an estimated $372K.
  • Kezar Life Sciences made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2093 holding.
  • Jim Simons first reported a position in Kezar Life Sciences in Q3 2019 and has held it in 27 quarters since.
  • Jim Simons's Kezar Life Sciences position peaked at $5.52M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.